التفاصيل البيبلوغرافية
| العنوان: |
Supplementary Material for: Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO |
| المؤلفون: |
Zaiss M. (11406080), Uhlig J. (11406083), Zahn M.-O. (11406086), Decker T. (4272631), Lehmann H.C. (11406089), Harde J. (11406092), Hogrefe C. (11406095), Vannier C. (11406098), Marschner N. (4149046) |
| سنة النشر: |
2021 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Medicine, Peripheral sensory and motor neuropathy, Chemotherapy, Oxaliplatin, Paclitaxel, Food supplement |
| الوصف: |
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect persisting after completion of neurotoxic chemotherapies. This observational study was designed to evaluate the effectiveness of the dietary supplement OnLife® (patented mixture of specific fatty acids and palmitoylethanolamide) in improving symptoms of CIPN in breast and colon cancer patients. Methods: Improvement of CIPN was evaluated in adult patients, previously treated with (neo)adjuvant paclitaxel- (breast cancer) or oxaliplatin-based (colon cancer) therapies, receiving OnLife® for 3 months after completion of chemotherapy. The primary endpoint was to compare the severity of peripheral sensory neuropathy (PSN) and peripheral motor neuropathy (PMN) before and at the end of OnLife® treatment. Secondary endpoints included the assessment of patient-reported quality of life and CIPN symptoms as assessed by questionnaires. Results: 146 patients ( n = 75 breast cancer patients and n = 71 colon cancer patients) qualified for analysis; 31.1% and 37.5% of breast cancer patients had an improvement of PSN and PMN, respectively. In colon cancer patients, PSN and PMN improved in 16.9% and 20.0% of patients, respectively. According to patient-reported outcomes, 45.9% and 37.5% of patients with paclitaxel-induced PSN and PMN, and 23.9% and 22.0% of patients with oxaliplatin-induced PSN and PMN experienced a reduction of CIPN symptoms, respectively. Conclusion: OnLife® treatment confirmed to be beneficial in reducing CIPN severity and in limiting the progression of neuropathy, more markedly in paclitaxel-treated patients and also in patients with oxaliplatin-induced CIPN. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/dataset/Supplementary_Material_for_Improving_Chemotherapy-Induced_Peripheral_Neuropathy_in_Patients_with_Breast_or_Colon_Cancer_after_End_of_Neo_adjuvant_Therapy_Results_from_the_Observational_Study_STEFANO/16585550 |
| DOI: |
10.6084/m9.figshare.16585550.v1 |
| الاتاحة: |
https://doi.org/10.6084/m9.figshare.16585550.v1 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.E31FAB92 |
| قاعدة البيانات: |
BASE |